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Abstract
Background: Non-invasive vagus nerve stimulation (nVNS) has been shown to be practical, safe, and well tolerated
for treating primary headache disorders. The recent multicenter, randomized, double-blind, sham-controlled PRESTO
trial provided Class I evidence that for patients with episodic migraine, nVNS significantly increases the probability
of having mild pain or being pain-free 2 h post stimulation. We report additional pre-defined secondary and other
end points from PRESTO that demonstrate the consistency and durability of nVNS efficacy across a broad range of
outcomes.
Methods: After a 4-week observation period, 248 patients with episodic migraine with/without aura were randomly
assigned to acute treatment of migraine attacks with nVNS (n = 122) or a sham device (n = 126) during a double-
blind period lasting 4 weeks (or until the patient had treated 5 attacks). All patients received nVNS therapy during
the subsequent 4-week/5-attack open-label period.
Results: The intent-to-treat population consisted of 243 patients. The nVNS group (n = 120) had a significantly
greater percentage of attacks treated during the double-blind period that were pain-free at 60 (P = 0.005) and
120 min (P = 0.026) than the sham group (n = 123) did. Similar results were seen for attacks with pain relief
at 60 (P = 0.025) and 120 min (P = 0.018). For the first attack and all attacks, the nVNS group had significantly
greater decreases (vs sham) in pain score from baseline to 60 min (P = 0.029); the decrease was also significantly greater
for nVNS at 120 min for the first attack (P = 0.011). Results during the open-label period were consistent with those of the
nVNS group during the double-blind period. The incidence of adverse events (AEs) and adverse device effects was low
across all study periods, and no serious AEs occurred.
Conclusions: These results further demonstrate that nVNS is an effective and reliable acute treatment for multiple
migraine attacks, which can be used safely while preserving the patient’s option to use traditional acute medications as
rescue therapy, possibly decreasing the risk of medication overuse. Together with its practicality and optimal tolerability
profile, these findings suggest nVNS has value as a front-line option for acute treatment of migraine.
Trial registration: ClinicalTrials.gov identifier: NCT02686034.
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Background
Standard pharmacologic agents for the acute treatment
of migraine can be limited by side effects, inconsistent
efficacy, contraindications, risk of drug interactions, and
their potential contribution to migraine chronification
and medication overuse headache [1–5]. Opioids should
be discouraged for the acute treatment of migraine due
to significant safety concerns and lack of documented
but remain frequently used in the emergency depart-
ment setting, which significantly increases healthcare
costs [6–9]. Practical alternatives are needed to address
this healthcare challenge. Non-invasive neuromodulation
therapies could represent a novel option for these pa-
tients [10, 11].
Non-invasive vagus nerve stimulation (nVNS; gam-
maCore®; electroCore, Inc., Basking Ridge, NJ, USA)
demonstrated efficacy in studies of acute migraine
treatment and has a strong safety and tolerability profile
[12–15]. The multicenter, randomized, double-blind,
sham-controlled PRESTO trial provided Class I evidence
that for patients with an episodic migraine, acute treat-
ment of migraine attacks with nVNS significantly in-
creases the probability of having mild pain or being
pain-free 2 h post stimulation [11]. The study also clearly
demonstrated the practicality, safety, and tolerability of
nVNS. Here, we report additional pre-defined secondary
and other end points from the PRESTO study to illustrate
the consistency and durability of nVNS effects across a
broad range of outcomes.
Methods
Study design
Complete details of the methodology of the multicenter,
randomized, double-blind, sham-controlled PRESTO
trial have been reported previously [11]. The study was
conducted across 10 Italian sites from January 11, 2016,
through March 31, 2017, and consisted of an observa-
tional period, double-blind period, and open-label
period (Fig. 1a). During the observational period, pa-
tients treated their migraine attacks with standard
medications according to their individual prescriptions.
Patients subsequently treated up to 5 migraine attacks
with nVNS or sham stimulation during the double-blind
period and up to 5 additional attacks with nVNS during
the open-label period; only 1 attack could be treated in a
48-h period.
Patients
Study patients were 18 to 75 years of age, had a previous
diagnosis of migraine with or without aura according to
the International Classification of Headache Disorders,
3rd edition (beta version) criteria [16], were < 50 years of
age at migraine onset, and had 3 to 8 migraine attacks
per month with < 15 headache days per month during
the last 6 months. Patients who were receiving prevent-
ive migraine medications at baseline (or other preventive
medications determined to potentially interfere with the
study) were required to have maintained a stable dose
and frequency of these medications during the 2 months
a
b
Fig. 1 PRESTO study design (a) and treatment protocol (b). Abbreviations: L, left; nvNS, non-invasive vagus nerve stimulation; R, right; Stim, stimulation;
Tx, treatment
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before enrollment and throughout the study; initiation
of new preventive medications was not permitted during
this period.
Interventions and study procedures
Patients were randomly assigned (1:1) to receive nVNS
or sham (variable block design [4, 6], stratified by site).
Full details of study randomization and blinding, as well
as information about the active and sham devices, have
been described previously [11].
Within 20 min of migraine pain onset, patients
self-administered bilateral 120-s stimulations (ie, 1
stimulation each to the right and left sides of the
neck) (Fig. 1b) and recorded post-treatment assess-
ments in their study diaries 15, 30, 60, and 120 min
and 24 and 48 h after completion of the initial bilat-
eral stimulations. Patients were instructed to repeat
the bilateral stimulations if pain had not improved at
the 15-min assessment, and those who were not
pain-free at the 120-min assessment had the option
of administering an additional set of bilateral stimula-
tions. Patients were asked to wait 120 min from the
first set of stimulations before using acute rescue
medication.
End points
Here, we present clinically relevant secondary and other
end points not included in the original PRESTO publica-
tion to provide a more comprehensive depiction of the
data set. Pain-free was defined as a score of 0 on the
4-point headache pain scale (with 0 indicating no pain
and 3 indicating severe pain), and pain relief was defined
as a score of 0 or 1 (both without use of rescue medica-
tion before 120 min) in a subject with pain of at least
moderate severity at baseline. Attacks with mild pain (ie,
a pain score of 1) at both baseline and the subsequent
time point of interest were considered treatment failures.
These definitions were used in assessment of the follow-
ing end points:
 Percentages of all treated attacks that achieved pain
freedom and pain relief at 30, 60, and 120 min for
the double-blind period and at 120 min for the
open-label period;
 Mean change in pain score from baseline to 30, 60,
and 120 min for the first attack and for all attacks in
the double-blind and open-label periods;
 Number of acute medications used per migraine
attack during the observational, double-blind, and
open-label periods;
 Sustained treatment response (defined as pain-free or
pain relief [without use of rescue medication] at
both 2 h and 24 h or at 2, 24, and 48 h) rates for the
first attack and all attacks for the double-blind and
open-label periods;
 Incidence of adverse events (AEs) and adverse
device effects (ADEs).
Statistical methods
All efficacy end points were evaluated using the intent-
to-treat (ITT) population, defined as all randomly
assigned patients who treated at least 1 migraine at-
tack in the double-blind period. Descriptive statistics
were used to summarize continuous variables (means
and 95% confidence intervals [CIs]) and categorical
variables (frequency counts, percentages, and 95% CIs).
Generalized linear mixed effects regression models were
used to estimate the proportion of all attacks that were
pain-free or had pain relief for the nVNS and sham
groups, allowing for both subject-specific and population-
averaged inferences in non-normally distributed data; P
values were from resulting F tests. Mean change from
baseline pain score was compared between treatment
groups via 2-sample t tests for the first attack and via lin-
ear mixed effects regression models. Poisson regression
was used to compare medication use per attack between
treatment groups. For sustained treatment response
(pain-free and pain relief), the nVNS and sham groups
were compared via the chi-square test or Fisher exact test,
as appropriate, for the first attack and via linear mixed
effects regression models for all attacks. All data were ana-
lyzed using SAS®9.4 (SAS Institute Inc., Cary, NC, USA).
Two-sided P values < 0.05 were considered statistically
significant.
Results
Patients
Complete descriptions of patient disposition, demo-
graphics, and baseline characteristics in PRESTO are
included in the original study publication [11]. The
ITT population consisted of 243 patients (nVNS, n =
120; sham, n = 123). Two hundred thirty-nine patients
entered the open-label period (nVNS, n = 117; sham,
n = 122); among these, 238 patients (> 99%) completed
this period (1 patient was lost to follow-up), with 220
(92%) treating at least 1 attack during the period. One
patient who treated at least 1 attack in and completed
the open-label period was not part of the ITT popula-
tion. Table 1 summarizes key demographics and other
key patient characteristics.
Efficacy: double-blind period
In the nVNS group, the percentage of all attacks that
were pain-free at 60 min (16.3%) and 120 min (22.9%)
was significantly greater than in the sham group (8.6%
and 14.8%, respectively; P < 0.05 for both time points)
(Fig. 2a). Similar significant results were seen for the
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percentage of attacks with pain relief (Fig. 2b), which
was 29.4% for the nVNS group and 20.3% for the
sham group at 60 min (P = 0.025) and 35.2% for the
nVNS group and 25.4% for the sham group at
120 min (P = 0.018).
For the first attack (Fig. 3a), the nVNS group had sig-
nificantly greater decreases (vs the sham group) in mean
pain score from baseline at 60 min (nVNS, 0.51; sham,
0.22; P = 0.029) and 120 min (nVNS, 0.62; sham, 0.23;
P = 0.011). For all attacks (Fig. 3c), the mean decrease
from baseline in pain score was significantly greater in
the nVNS group (0.42) than in the sham group (0.22) at
60 min (P = 0.029) but not at 120 min (nVNS, 0.50;
sham, 0.28; P = 0.057).
During the observational (run-in) period, study
patients used a mean of 0.86 acute medications per at-
tack. Acute medication use decreased during the
double-blind period to 0.45 medications per attack in
the nVNS group and 0.55 medications per attack in the
sham group (P = 0.055).
Sustained pain-free and pain relief response rates were
high in both the nVNS and sham groups at 24 h (≥75%)
and 48 h (≥58%) for both the first attack and all attacks
(Table 2).
Efficacy: open-label period
The percentages of all treated attacks that were pain-free
(23.3%) or had pain relief (38.1%) at 120 min during the
open-label period were similar to those of the nVNS
group during the double-blind period (Fig. 2). Mean
changes from baseline in pain score during the
open-label period for the first attack (30 min, −or t;
60 min, − 0.56; 120 min, − 0.61) and for all treated at-
tacks (30 min, − 0.38; 60 min, − 0.50; 120 min, − 0.57)
were similar to those seen in the nVNS group during
the double-blind period (Fig. 3). A mean of 0.46 acute
medications per attack were used during the
open-label period, which was similar to that of the
Table 1 Demographics and other key patient characteristics
Characteristic nVNS (n = 120) Sham (n = 123) Total (N = 243)
Age, mean (SD), y 38.8 (11.0) 39.6 (11.8) 39.2 (11.4)
Female sex, No. (%) 95 (79.2) 91 (74.0) 186 (76.5)
Diagnosis, No. (%)
Migraine with aura 8 (6.7) 9 (7.3) 17 (7.0)
Migraine without aura 112 (93.3) 114 (92.7) 226 (93.0)
Current preventive medication
use, No. (%)
42 (35.0) 35 (28.5) 77 (31.7)
No. of acute medication days
per mo,a mean (SD)
5.6 (1.7) 5.3 (1.7) 5.5 (1.7)
Attack severity at onset for all treated
attacks in DB period, No. (%)
n = 359b n = 329b NA
Mild 113 (31.5) 105 (31.9)
Moderate 156 (43.5) 166 (50.5)
Severe 90 (25.1) 58 (17.6)
Attack severity at onset for first
treated attack in DB period, No. (%)
n = 119b n = 119b NA
Mild 40 (33.6) 46 (38.7)
Moderate 51 (42.9) 55 (46.2)
Severe 28 (23.5) 18 (15.1)
© 2018 Tassorelli C, Grazzi L, de Tommaso M, Pierangeli G, Martelletti P, Rainero I,
Dorlas S, Geppetti P, Ambrosini A, Sarchielli P, Liebler E, Barbanti P, PRESTO Study
Group (2018) Non-invasive vagus nerve stimulation as acute therapy for migraine: the
randomized PRESTO study [published online June 15, 2018]. Neurology:doi:https://
doi.org/10.1212/WNL.0000000000005857. www.neurology.org. Adapted with permission
Abbreviations: DB Double-blind, NA Not applicable, nVNS Non-invasive vagus nerve
stimulation, SD Standard deviation
aNo. of days the patient typically takes acute migraine medication per month. b
Patients with no reported baseline severity were excluded from this analysis
a b
Fig. 2 Percentage of all treated attacks that were pain-free (a) or had pain relief (b) during the double-blind and open-label periods (ITT population,
N = 243). Generalized linear mixed effects regression models were used to estimate the proportion of successful responses, allowing for both subject-
specific and population-averaged inferences in non-normally distributed data. P values are from resulting F tests. Models were adjusted for subject’s
pain score at baseline, use of preventive therapies, and indicator or presence of aura. Abbreviations: CI, confidence interval; ITT, intent-to-treat; nVNS,
non-invasive vagus nerve stimulation
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nVNS group during the double-blind period (0.45
acute medications per attack) and was decreased from
the observation period by 0.40 acute medications per
attack. Sustained treatment response during the
open-label period was generally similar to or greater
than that seen in the nVNS group during the
double-blind period (Table 2).
Safety
As previously reported [11], the incidence of AEs and
ADEs was low across all study periods, and no serious
AEs occurred. The only ADE reported by > 1 patient
during the open-label period was vertigo, which was re-
ported by 2 patients (1%).
Discussion
These additional results from the PRESTO study further
demonstrate that nVNS is superior to sham across a
broad range of relevant end points. In the nVNS group,
significantly greater percentages of all attacks were
pain-free or had pain relief at 60 and 120 min than in
the sham group. The nVNS group also had significantly
greater decreases from baseline in mean pain score for
the first attack (60 and 120 min) and for all attacks
(60 min). Among nVNS-treated attacks that were pain-
free at 120 min, > 75% had a sustained response at 24 h.
Ninety-eight percent of patients in the ITT population
completed the open-label period, suggesting that the
benefit from nVNS was maintained and that nVNS is a
a b
c d
Fig. 3 Mean change in pain score from baseline for first attack during the double-blind (a) and open-label (b) periods and for all attacks during
the double-blind (c) and open-label Periods (d). P values for first attack are from 2-sample t tests. For all attacks, linear mixed effects regression
models were used to estimate the change in pain score between baseline and 30, 60, and 120 min, allowing for both subject-specific and population-
averaged inferences. Abbreviations: CI, confidence interval; nvNS, non-invasive vagus nerve stimulation
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durable acute therapy. The results for the total population
during the open-label period were generally similar to
those seen for the nVNS group during the double-blind
period. Throughout the study, the incidence of AEs and
ADEs was low, and no serious AEs were reported.
The findings from PRESTO are consistent with
those from other clinical studies of acute nVNS use in
migraine [12, 13]. They are supported by several po-
tential mechanisms of action for the acute benefits of
vagus nerve stimulation, including inhibition of cen-
tral excitability through suppression of glutamate re-
lease, suppression of acute nociceptive activation of
trigeminocervical neurons, and curbing expression of
proteins associated with central sensitization of tri-
geminal neurons [17–19].
The high rates of sustained 24-h pain-free response to
nVNS seen in PRESTO (> 75%) stand in contrast to the
lower rates reported for oral triptans (10%–30%) and
single-pulse transcranial magnetic stimulation (29%) [10,
20]. The protocol of the single-pulse transcranial magnetic
stimulation study called for a study population restricted
to patients with aura and a treatment time that was inde-
pendent from the onset of pain (ie, within 1 h after aura
onset), making comparison with the nVNS findings chal-
lenging [10]. The majority of patients enrolled in the
PRESTO study had migraine without aura, and nVNS was
delivered promptly after the onset of migraine pain (ie,
within 20 min) [11]. In the majority of the triptan clinical
trials, treatment was not initiated until migraine pain
reached a moderate/severe level, partially due to the desire
to avoid unnecessary adverse effects [20, 21]. Consistent
with findings from PRESTO [22], rates of sustained re-
sponse appear to be higher with the use of triptans during
the early stages of migraine (34%–53%) than during the
later stages (19%–31%) [21, 23]. These observations
suggest that there are benefits to treating early in the
course of migraine attacks—in a sense, intervening be-
fore the migraine process is fully activated. High rates
of sustained pain-free response in both the nVNS and
sham groups in PRESTO suggest that intervention early
in the course of migraine might confer benefits, irre-
spective of the treatment.
Together with findings from multiple previous stud-
ies [12–15, 24–26], these results from PRESTO further
highlight the clinical utility, practicality, and flexibility
of nVNS. Across the double-blind and open-label pe-
riods, nVNS was used to treat > 900 migraine attacks,
with data collected at multiple time points for each at-
tack, demonstrating its consistent efficacy, safety, and
tolerability as acute treatment for these attacks. nVNS
can be used as monotherapy or in conjunction with
other treatments without risk of pharmacologic inter-
actions, offering a clinical versatility that other acute
migraine treatments lack. These advantages, along with
its convenience and ease of use, make nVNS an ap-
pealing and pragmatic option for early, adjunctive,
and/or frequent use in the acute treatment of migraine.
nVNS could also help minimize the risk of medication
overuse associated with traditional acute treatments and
reduce the frequency of opioid use for the acute treatment
of migraine in the emergency department setting.
This study has a number of limitations. The selection
of an appropriate sham device in neuromodulation
studies is challenging. In accordance with previous rec-
ommendations to ensure maintenance of the study
blind [27], the sham device used in PRESTO produced
an active signal that could be perceived by the user but
was not designed to stimulate the vagus nerve; recent
data suggest that the strength of the sham device’s sig-
nal may have inadvertently activated the vagus nerve
and could have inflated the responses to sham treat-
ment across all end points [28]. This phenomenon, which
merits further investigation, may have been related to a
psychobiological placebo effect but more likely resulted
from the unanticipated physiologically active signal that
Table 2 Sustained response at 24 and 48 h post-treatment
Double-blind Period Open-label Period
nVNS Sham P Value nVNS
% (n/N)
(95% CI)
% (n/N)
(95% CI)
% (n/N)
(95% CI)
All Attacks
Pain-free
24 h 79.0 (71/93)
(67.9, 87.1)
83.7 (54/66)
(69.9, 91.9)
0.532a 80.8 (118/146)
(73.5, 86.6)
48 h 65.7 (59/93)
(53.3, 76.3)
71.2 (46/66)
(56.5, 82.5)
0.537a 70.3 (102/146)
(61.6, 77.7)
Pain relief
24 h 80.9 (109/138)
(72.3, 87.3)
80.3 (78/99)
(69.4, 87.9)
0.916a 80.5 (185/230)
(74.5, 85.3)
48 h 74.1 (99/138)
(64.0, 82.1)
72.1 (70/99)
(60.7, 81.3)
0.775a 71.9 (165/230)
(65.2, 77.7)
First Attack
Pain-free
24 h 75.0 (27/36)
(57.8, 87.9)
84.6 (22/26)
(65.1, 95.6)
0.359b 75.4 (46/61)
(62.7, 85.5)
48 h 58.3 (21/36)
(40.8, 74.5)
69.2 (18/26)
(48.2, 85.7)
0.381b 65.6 (40/61)
(52.3, 77.3)
Pain relief
24 h 77.3 (58/75)
(66.2, 86.2)
79.3 (46/58)
(66.7, 88.8)
0.784b 78.8 (108/137)
(71.0, 85.3)
48 h 69.3 (52/75)
(57.6, 79.5)
71.0 (41/58)
(57.3, 81.9)
0.866b 70.1 (96/137)
(61.7, 77.6)
Abbreviations: CI Confidence interval, nVNS Non-invasive vagus nerve stimulation
aGeneralized linear mixed effects regression models were used to estimate the
proportion of successful responses, allowing for both subject-specific and
population-averaged inferences in non-normally distributed data. bFrom chi-square
test or Fisher exact test, as appropriate
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may have decreased the difference in therapeutic gain seen
between the nVNS and sham groups [11].
During both the double-blind and open-label periods,
the mean number of acute medications used per migraine
attack was substantially lower than that seen during the
observational period. Such a decrease in medication use
could be interpreted as evidence of treatment efficacy;
however, these results must be interpreted with caution,
as patients were encouraged to refrain from using acute
medications for 120 min after stimulation with the study
device. This study limitation most likely contributed to de-
creases in acute medication use in both the nVNS and
sham groups during the double-blind period and may par-
tially explain the lack of significance between treatment
groups for this end point.
Conclusions
These results from clinically relevant secondary and other
end points of the PRESTO study demonstrate the efficacy
and reliability of nVNS for the acute treatment of mi-
graine. nVNS provided dependable efficacy for the suc-
cessful treatment of multiple attacks and can be used
safely while preserving a patient’s option to use additional
acute medications as rescue therapy, thus potentially de-
creasing the risk of medication overuse. Together, these
findings highlight the flexibility and practicality of nVNS
as a front-line option for acute migraine attacks.
Abbreviations
ADE: Adverse device effect; AE: Adverse event; CI: Confidence interval; DB: Double-
blind; ITT: Intent to treat; L: Left; NA: Not applicable; nVNS: Non-invasive
vagus nerve stimulation; R: Right; SD: Standard deviation; Stim: Stimulation;
Tx: Treatment
Acknowledgments
Medical writing support was provided by Elizabeth Barton, MS, of MedLogix
Communications, LLC, in cooperation with the authors. Statistical analyses were
conducted by Candace McClure, PhD, of North American Science Associates Inc.
Co-investigators:
The PRESTO Study Group
Coinvestigators are listed by study site: 1. Headache Science Centre, National
Neurological Institute C. Mondino Fo undation and University of Pavia: Cristina
assorelli, MD, PhD (Principal Investigator); Vito Bitetto (Subinvestigator);
Roberto De Icco, MD (Subinvestigator); Daniele Martinelli, MD (Subinvestigator);
Grazia Sances, MD (Subinvestigator); Monica Bianchi, MD (Research Nurse); 2.
Carlo Besta Neurological Institute and Foundation: Licia Grazzi, MD (Principal
Investigator); Anna Maria Padovan (Subinvestigator); 3. University of Bari Aldo
Moro: Marina de Tommaso, MD, PhD (Principal Investigator); Katia Ricci
(Subinvestigator); Eleonora Vecchio, MD, PhD (Subinvestigator); 4. IRCCS
Istituto delle Scienze Neurologiche di Bologna: Pietro Cortelli, MD, PhD
(Principal Investigator); Sabina Cevoli, MD, PhD (Subinvestigator); Giulia
Pierangeli, MD, PhD (Subinvestigator); Rossana Terlizzi, MD (Subinvestigator); 5.
Sapienza University of Rome: Paolo Martelletti, MD, PhD (Principal
Investigator); Andrea Negro, MD (Subinvestigator); Gabriella Addolorata
Chiarillo (Research Nurse); 6. University of Turin: Innocenzo Rainero, MD,
PhD (Principal Investigator); Paola De Martino, MD, PhD
(Subinvestigator); Annalisa Gai, MD (Subinvestigator); Flora Govone, MD
(Subinvestigator); Federica Masuzzo, MD (Subinvestigator); Elisa Rubino,
MD, PhD (Subinvestigator); Maria Claudia Torrieri, MD (Subinvestigator);
Alessandro Vacca, MD (Subinvestigator); 7. University Hospital of Careggi:
Pierangelo Geppetti, MD, PhD (Principal Investigator); Alberto Chiarugi, MD,
PhD (Subinvestigator); Francesco De Cesaris (Subinvestigator); Simone Li Puma
(Subinvestigator); Chiara Lupi (Subinvestigator); Ilaria Marone (Subinvestigator);
8. IRCCS Neuromed: Anna Ambrosini, MD, PhD (Principal Investigator);
Armando Perrotta, MD, PhD (Subinvestigator); 9. Santa Maria della
Misericordia Hospital: Paola Sarchielli, MD, PhD (Principal Investigator);
Laura Bernetti, MD (Subinvestigator); Ilenia Corbelli, MD, PhD (Subinvestigator);
Michele Romoli, MD (Subinvestigator); Simone Simoni, MD (Subinvestigator);
Angela Verzina, MD (Subinvestigator); 10. IRCCS San Raffaele Pisana: Piero
Barbanti, MD, PhD (Principal Investigator); Cinzia Aurilia, MD (Subinvestigator);
Gabriella Egeo, MD, PhD (Subinvestigator); Luisa Fofi, MD (Subinvestigator).
electroCore Study Team: Eric Liebler (Senior Vice President, Neurology);
Annelie Andersson (Senior Director, Clinical Director); Lia Spitzer (Senior
Director, Clinical/Study Manager); Juana Marin, MD (Clinical Advisor, Safety
Monitor); Candace McClure, PhD (North American Science Associates Inc.,
Statistician); Lisa Thackeray, MS (North American Science Associates Inc.,
Statistician), Maria Giovanna Baldi (Monitor); Daniela Di Maro (Monitor).
Funding
This study was sponsored by electroCore, Inc.
Availability of data and materials
Any data not published within this article will be publicly available at
ClinicalTrials.gov with the identifier NCT02686034. Individual participant
data will not be shared.
Authors’ contributions
LG, EL, and CT contributed to the PRESTO study design. All primary investigators
were involved in participant recruitment and treatment for the PRESTO study. All
authors participated in data collection, interpretation, and validation and had full
access to all study data. CT and EL were involved in data analysis. EL drafted and
revised the manuscript for content in cooperation with all authors. All authors
reviewed, critiqued, and contributed to revision of the manuscript content and
provided approval of the final manuscript draft to be submitted to the Journal of
Headache and Pain. The principal author, PM, takes responsibility for all aspects of
the work and for ensuring that questions related to the accuracy or integrity of
any part of the work were appropriately investigated and resolved.
Ethics approval and consent to participate
Investigators obtained local ethics committee approval of the protocol, which
was registered at ClinicalTrials.gov (NCT02686034). All patients provided written
informed consent in advance of study participation.
Consent for publication
Not applicable.
Competing interests
P. Martelletti has received research grants, advisory board fees, or travel fees
from ACRAF; Allergan S.p.A.; Amgen Inc.; electroCore, Inc.; Novartis AG; and
Teva Pharmaceutical Industries Ltd.
L. Grazzi has received consultancy and advisory fees from Allergan S.p.A. and
electroCore, Inc.
G. Pierangeli has nothing to disclose.
I. Rainero has received consultancy fees from electroCore, Inc., and Mylan
N.V. and research grants from the European Commission – Horizon 2020. He
is also a principal investigator for RCTs sponsored by Axovant Sciences Ltd.
and TauRx Pharmaceuticals Ltd.
P. Geppetti has received consultancy fees from Allergan S.p.A.; electroCore,
Inc.; Evidera; Novartis AG; Pfizer Inc.; and Sanofi S.p.A. and research grants
from Chiesi Farmaceutici S.p.A. He is also a principal investigator for RCTs
sponsored by Eli Lilly and Company; Novartis AG; and Teva Pharmaceutical
Industries Ltd.
A. Ambrosini has received consultancy fees from Almirall, S.A., and travel
grants from Allergan S.p.A., Almirall, S.A., and Novartis.
P. Sarchielli has received clinical study fees from Allergan S.p.A.
P. Barbanti has received consultancy fees from Allergan S.p.A.;
electroCore, Inc.; Janssen Pharmaceuticals, Inc.; Lusofarmaco; and
Visufarma and advisory fees from Abbott Laboratories; Merck & Co., Inc.;
Novartis AG; and Teva Pharmaceutical Industries Ltd. He is also a
principal investigator for RCTs sponsored by Alder BioPharmaceuticals
Inc.; Eli Lilly and Company; GlaxoSmithKline Pharmaceuticals Ltd.; and
Teva Pharmaceutical Industries Ltd.
Martelletti et al. The Journal of Headache and Pain          (2018) 19:101 Page 7 of 8
C. Tassorelli has consulted for Allergan S.p.A.; electroCore, Inc.; Eli Lilly and
Company; and Novartis AG and has received research grants from the
European Commission and the Italian Ministry of Health. She is also a
principal investigator or collaborator for RCTs sponsored by Alder
BioPharmaceuticals Inc.; Eli Lilly and Company; Novartis; and Teva
Pharmaceutical Industries Ltd.
E. Liebler is an employee of electroCore, Inc., and receives stock ownership.
M. de Tommaso has received advisory fees from Allergan S.p.A.; Neopharmed;
and Pfizer Inc.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Clinical and Molecular Medicine, Sapienza University, Rome,
Italy. 2Headache and Pain Unit, Istituto di Ricovero e Cura a Carattere
Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy. 3Neuroalgology Unit,
Carlo Besta Neurological Institute and Foundation, Milan, Italy. 4IRCCS Istituto
delle Scienze Neurologiche di Bologna, Bologna, Italy. 5Department of
Neuroscience, University of Turin, Turin, Italy. 6Headache Centre, University
Hospital of Careggi, Florence, Italy. 7IRCCS Neuromed, Pozzilli, IS, Italy.
8Neurologic Clinic, Santa Maria della Misericordia Hospital, Perugia, Italy.
9Headache Science Centre, IRCCS C. Mondino Foundation, Pavia, Italy.
10Department of Brain and Behavioral Sciences, University of Pavia, Pavia,
Italy. 11electroCore, Inc., Basking Ridge, NJ, USA. 12Neurophysiology and Pain
Unit, University of Bari Aldo Moro, Bari, Italy.
Received: 9 August 2018 Accepted: 3 October 2018
References
1. Lopes M, Dunn JD, Calhoun AH, Rapoport AM (2012) Concepts in acute
migraine management: clinical and managed care perspectives. Am J
Pharm Benefits 4(5):201–206
2. Negro A, Koverech A, Martelletti P (2018) Serotonin receptor agonists in the
acute treatment of migraine: a review on their therapeutic potential. J Pain
Res 11:515–526. https://doi.org/10.2147/JPR.S132833
3. Puledda F, Messina R, Goadsby PJ (2017) An update on migraine: current
understanding and future directions. J Neurol 264(9):2031–2039. https://doi.
org/10.1007/s00415-017-8434-y
4. Rolan PE (2012) Drug interactions with triptans: which are clinically significant?
CNS Drugs 26(11):949–957. https://doi.org/10.1007/s40263-012-0002-5
5. Bigal ME, Lipton RB (2009) Overuse of acute migraine medications and
migraine chronification. Curr Pain Headache Rep 13(4):301–307
6. Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P (2018) Direct and
indirect healthcare resource utilization and costs among migraine patients in
the United States. Headache 58(5):700–714. https://doi.org/10.1111/head.13275
7. Friedman BW, Irizarry E, Solorzano C, Latev A, Rosa K, Zias E, Vinson DR, Bijur
PE, Gallagher EJ (2017) Randomized study of IV prochlorperazine plus
diphenhydramine vs IV hydromorphone for migraine. Neurology 89(20):
2075–2082. https://doi.org/10.1212/WNL.0000000000004642
8. Friedman BW, West J, Vinson DR, Minen MT, Restivo A, Gallagher EJ (2015)
Current management of migraine in US emergency departments: an
analysis of the National Hospital Ambulatory Medical Care Survey.
Cephalalgia 35(4):301–309. https://doi.org/10.1177/0333102414539055
9. Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, Tepper D (2016)
Management of Adults with Acute Migraine in the emergency department: the
American headache society evidence assessment of parenteral
pharmacotherapies. Headache 56(6):911–940. https://doi.org/10.1111/head.12835
10. Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH,
Fischell RE, Ruppel PL, Goadsby PJ (2010) Single-pulse transcranial magnetic
stimulation for acute treatment of migraine with aura: a randomised,
double-blind, parallel-group, sham-controlled trial. Lancet Neurol 9(4):373–
380. https://doi.org/10.1016/S1474-4422(10)70054-5
11. Tassorelli C, Grazzi L, de Tommaso M, et al. (2018) Non-invasive vagus nerve
stimulation as acute therapy for migraine: the randomized PRESTO study.
Neurology 91(4):e364–e373.
12. Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone G (2015) Non-
invasive vagus nerve stimulation for acute treatment of high-frequency and
chronic migraine: an open-label study. J Headache Pain 16:61. https://doi.
org/10.1186/s10194-015-0542-4
13. Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA (2014) Effect of
noninvasive vagus nerve stimulation on acute migraine: an open-label pilot
study. Cephalalgia 34(12):986–993. https://doi.org/10.1177/0333102414524494
14. Kinfe TM, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon BJ, Vatter H
(2015) Cervical non-invasive vagus nerve stimulation (nVNS) for preventive
and acute treatment of episodic and chronic migraine and migraine-
associated sleep disturbance: a prospective observational cohort study. J
Headache Pain 16:101. https://doi.org/10.1186/s10194-015-0582-9
15. Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S,
Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR, Group ES (2016)
Chronic migraine headache prevention with noninvasive vagus nerve
stimulation: the EVENT study. Neurology 87(5):529–538. https://doi.org/10.
1212/WNL.0000000000002918
16. (2013) The International Classification of Headache Disorders, 3rd edition (beta
version). Cephalalgia 33(9):629–808. https://doi.org/10.1177/0333102413485658
17. Akerman S, Simon B, Romero-Reyes M (2017) Vagus nerve stimulation
suppresses acute noxious activation of trigeminocervical neurons in animal
models of primary headache. Neurobiol Dis 102:96–104. https://doi.org/10.
1016/j.nbd.2017.03.004
18. Hawkins JL, Cornelison LE, Blankenship BA, Durham PL (2017) Vagus nerve
stimulation inhibits trigeminal nociception in a rodent model of episodic
migraine. Pain Rep 2(6):e628. https://doi.org/10.1097/PR9.0000000000000628
19. Oshinsky ML, Murphy AL, Hekierski H Jr, Cooper M, Simon BJ (2014)
Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia.
Pain 155(5):1037–1042. https://doi.org/10.1016/j.pain.2014.02.009
20. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-
HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
Lancet 358(9294):1668–1675. https://doi.org/10.1016/S0140-6736(01)06711-3
21. Cady R, Elkind A, Goldstein J, Keywood C (2004) Randomized, placebo-
controlled comparison of early use of frovatriptan in a migraine attack
versus dosing after the headache has become moderate or severe. Curr
Med Res Opin 20(9):1465–1472. https://doi.org/10.1185/030079904X2745
22. Grazzi L, Tassorelli C, de Tommaso M, Pierangeli G, Martelletti P, Rainero I,
Geppetti P, Ambrosini A, Sarchielli P, Liebler E, Barbanti P (2018) Practical
and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the
acute treatment of migraine: post hoc assessment of the randomized,
sham-controlled, double-blind PRESTO trial [abstract MTIS2018-059].
Cephalalgia 38(1S):42. https://doi.org/10.1177/0333102418789865
23. Cady RK, Sheftell F, Lipton RB, O’Quinn S, Jones M, Putnam DG, Crisp A,
Metz A, McNeal S (2000) Effect of early intervention with sumatriptan on
migraine pain: retrospective analyses of data from three clinical trials. Clin
Ther 22(9):1035–1048
24. Gaul C, Diener HC, Silver N, Magis D, Reuter U, Andersson A, Liebler EJ, Straube A,
Group PS (2016) Non-invasive vagus nerve stimulation for prevention and acute
treatment of chronic cluster headache (PREVA): a randomised controlled study.
Cephalalgia 36(6):534–546. https://doi.org/10.1177/0333102415607070
25. Goadsby PJ, de Coo IF, Silver N, Tyagi A, Ahmed F, Gaul C, Jensen RH,
Diener HC, Rabe K, Straube A, Liebler E, Marin J, Ferrari MD, Group AS
(2018) Non-invasive vagus nerve stimulation for the acute treatment of
episodic and chronic cluster headache: findings from the randomized,
double-blind, sham-controlled ACT2 study. Cephalalgia 38(5):959–969.
https://doi.org/10.1177/0333102417744362
26. Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR,
Liebler EJ, Rubenstein Engel E, Tepper SJ, Group AS (2016) Non-invasive vagus
nerve stimulation for the acute treatment of cluster headache: findings from
the randoInnocenzo Raineromized, double-blind, sham-controlled ACT1 study.
Headache 56(8):1317–1332. https://doi.org/10.1111/head.12896
27. Asano E, Goadsby PJ (2013) How do we fashion better trials for
neurostimulator studies in migraine? Neurology 80(8):694. https://doi.org/10.
1212/WNL.0b013e3182825174
28. Moeller M, Schroeder CF, May A (2018) Comparison of active and
“sham” non-invasive vagal nerve stimulation on lacrimation in healthy
volunteers [abstract PS76]. Headache 58(suppl 2):135–136. https://doi.
org/10.1111/head.13306
Martelletti et al. The Journal of Headache and Pain          (2018) 19:101 Page 8 of 8
